CN1280292C - 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物 - Google Patents

用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物 Download PDF

Info

Publication number
CN1280292C
CN1280292C CNB028271122A CN02827112A CN1280292C CN 1280292 C CN1280292 C CN 1280292C CN B028271122 A CNB028271122 A CN B028271122A CN 02827112 A CN02827112 A CN 02827112A CN 1280292 C CN1280292 C CN 1280292C
Authority
CN
China
Prior art keywords
alkyl
compound
hydrogen
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028271122A
Other languages
English (en)
Chinese (zh)
Other versions
CN1615309A (zh
Inventor
W·姜
Z·隋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of CN1615309A publication Critical patent/CN1615309A/zh
Application granted granted Critical
Publication of CN1280292C publication Critical patent/CN1280292C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
CNB028271122A 2001-11-14 2002-11-12 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物 Expired - Fee Related CN1280292C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33297701P 2001-11-14 2001-11-14
US60/332,977 2001-11-14

Publications (2)

Publication Number Publication Date
CN1615309A CN1615309A (zh) 2005-05-11
CN1280292C true CN1280292C (zh) 2006-10-18

Family

ID=23300709

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028271122A Expired - Fee Related CN1280292C (zh) 2001-11-14 2002-11-12 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物

Country Status (14)

Country Link
US (1) US6686349B2 (https=)
EP (1) EP1448562B1 (https=)
JP (1) JP4484517B2 (https=)
CN (1) CN1280292C (https=)
AT (1) ATE368040T1 (https=)
CA (1) CA2467269C (https=)
CY (1) CY1107747T1 (https=)
DE (1) DE60221425T2 (https=)
DK (1) DK1448562T3 (https=)
ES (1) ES2289159T3 (https=)
MY (1) MY128241A (https=)
PT (1) PT1448562E (https=)
TW (1) TWI264437B (https=)
WO (1) WO2003042213A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629299A1 (de) * 1996-07-20 1998-01-22 Agfa Gevaert Ag Verfahren und Vorrichtung zum Aufnehmen einer Bildinformation
US6800625B2 (en) * 2002-06-19 2004-10-05 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1914235A1 (en) * 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN110862391B (zh) * 2019-11-13 2020-09-25 株洲千金药业股份有限公司 一种他达拉非杂质g的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH625521A5 (https=) 1976-10-15 1981-09-30 Sandoz Ag
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
ES2289159T3 (es) 2008-02-01
CA2467269A1 (en) 2003-05-22
DE60221425T2 (de) 2008-06-26
DE60221425D1 (de) 2007-09-06
TWI264437B (en) 2006-10-21
EP1448562B1 (en) 2007-07-25
ATE368040T1 (de) 2007-08-15
DK1448562T3 (da) 2007-09-24
CA2467269C (en) 2011-04-05
HK1069169A1 (en) 2005-05-13
PT1448562E (pt) 2007-08-31
CN1615309A (zh) 2005-05-11
US20030144268A1 (en) 2003-07-31
CY1107747T1 (el) 2013-04-18
MY128241A (en) 2007-01-31
JP4484517B2 (ja) 2010-06-16
EP1448562A1 (en) 2004-08-25
TW200408640A (en) 2004-06-01
JP2005511626A (ja) 2005-04-28
WO2003042213A1 (en) 2003-05-22
US6686349B2 (en) 2004-02-03

Similar Documents

Publication Publication Date Title
CN1280292C (zh) 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
CN1255403C (zh) 用作磷酸二酯酶抑制剂的β－咔啉衍生物
CN1136219C (zh) 用于治疗阳痿的吡唑并嘧啶酮衍生物
CN1250549C (zh) 吲哚衍生物及其作为5－ht2b和5－ht2c受体配体的应用
CN1281608C (zh) 新氮杂－吲哚基衍生物
CN1426413A (zh) 咪唑并吡啶衍生物
AU2001261167A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
CN1337963A (zh) 吡嗪并(氮杂)吲哚衍生物
EP1534707B9 (en) Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
CN1344257A (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
US6077841A (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
JP4169149B2 (ja) 化学的化合物
CN1479619A (zh) 吡唑并[4,3-d]嘧啶类化合物的用途
CN100347174C (zh) 杂环并嘧啶酮衍生物、制备方法和用途
HK1069169B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
HK1051368B (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
HK1050635A (en) Use of thienopyrimidines
HK1024243A (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061018

Termination date: 20151112

CF01 Termination of patent right due to non-payment of annual fee